Medical News: Cancer Biomarkers Missing in Action - Ovarian Cancer - Medscape

With a handful of possible exceptions, Diamandis wrote, "very few, if any, molecules have been identified that are expressed only by a cancer tissue but not by the corresponding normal tissue."
Cancer biomarkers are missing in action despite the availability of "highly sophisticated and powerful technologies" to discover them, as well as large investments, Diamandis wrote, adding that the last biomarker approved by the FDA -- in 2009 -- was HE4 protein, indicated for monitoring recurrence but not early detection of ovarian cancer."

Action Points  

---

• Note that this commentary documents the hazards of reports on promising biomarkers for cancer screening.



• The author points out that one of the major problems is finding biomarkers released in significant amounts from asymptomatic (usually small) tumors, but not from normal tissues.

Expert Analysis: Clinical Care Options Oncology - Ovarian Cancer

INDEPENDENT CONFERENCE COVERAGE 2010 American Society of Clinical Oncology Annual Meeting* *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
	To: CCO member From: Thomas J. Herzog, MD Columbia University College of Physicians and Surgeons New York, New York Subject: CME/CE-Certified Expert Analysis From Chicago Click to Access: Ovarian Cancer
	While attending the clinical oncology meeting in Chicago, Illinois, I met with Bradley J. Monk, MD, to review the clinical implications of recent studies in ovarian cancer. Our discussion is available on the Clinical Care Options Web site as a CME/CE-certified Expert Analysis. Select topics include: Bevacizumab-Based First-line Regimen and Maintenance Therapy for Advanced Ovarian Cancer First-line Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin, Followed by Paclitaxel Maintenance for Advanced Epithelial Ovarian Cancer Frontline PLD/Carboplatin vs Paclitaxel/Carboplatin for Advanced Ovarian Cancer Exploration of PARP Inhibitors in Ovarian Cancer With and Without BRCA Mutations New Antiangiogenesis Inhibitor for the Treatment of Recurrent Ovarian Cancer: AMG 386 Novel Monoclonal Antibody for the Treatment of Platinum-Sensitive Epithelial Ovarian Cancer: Farletuzumab Novel Vincristine-Based Agent for the Treatment of Platinum-Resistant Advanced Ovarian Cancer: EC125 Nab-Paclitaxel Plus Bevacizumab in Platinum-Resistant Primary Epithelial Ovarian Cancer or Primary Peritoneal Cancer Novel Irinotecan-Based Agent for the Treatment of Platinum-Resistant/Refractory Ovarian Cancer: NKTR-102 Platinum-Free Interval Extension With Trabectedin/PLD in Partially Platinum-Sensitive Recurrent Ovarian Cancer 2-Step Screening Strategy for Ovarian Cancer Using Annual CA-125 Measurement and Possible Transvaginal Ultrasound To review this CME/CE-certified Expert Analysis, click here. This Expert Analysis is located online at: http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202010.aspx

Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey - full free access

Facebook loophole reveals names, pictures with sign-on errors | Security - CNET News

Facebook loophole reveals names, pictures with sign-on errors | Security - CNET News

Expert Opinion: full free access for the next 7 days

Note: so far I have scanned the article as below which includes references to ovarian cancer;
Tip:  click on the titles below and then go to link clicking on the website which will bring you to the document :

• Treatment of thromboembolism in cancer patients
  Marina Panova-Noeva, Anna Falanga

index




To view this in your browser, click here: http://informahealthcare.msgfocus.com/q/18HKWto1lavLlBA/wv

Preclinical > Phase I > Phase II > Phase III > Launch" src="http://marketing.informahealthcare.com/client_work/7876_eo_html_template_1/header_top.gif" border="0" height="104" width="555">

A week's free online access to this month's most read Expert Opinion articles

Dear Colleague, Listed below are a selection of stand-out articles that have been handpicked by our editorial team from Expert Opinion. Better still, whether you are an Expert Opinion subscriber or not, you can view the articles below in full for the next 7 days. So why not forward these to your friends and colleagues too...? Please note to access these articles in full, you must use the links below.

This month's Editors' Picks: A safety assessment of tumor necrosis factor antagonists during pregnancy Vanessa C Osting, John D Carter Treatment of thromboembolism in cancer patients Marina Panova-Noeva, Anna Falanga Computational systems approach for drug target discovery Nagasuma Chandra Re-overcoming barriers in translating biomarkers to clinical practice Andrea Staratschek-Jox, Joachim L Schultze Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies Ichiro Takada, Alexander P Kouzmenko, Shigeaki Kato Biosimilars: current status and future directions Simon D Roger Advances in PEGylation of important biotech molecules: delivery aspects Sinéad M Ryan, Giuseppe Mantovani, Xuexuan Wang, et al.

In addition to the articles above, Expert Opinion is offering you 30 days FREE access to the entire journal portfolio. Simply click on the link below and start to benefit from the unrivalled coverage that Expert Opinion offers. Apply for your free trial today Should you have any questions about Expert Opinion, please feel free to contact me by simply replying to this e-mail. Yours faithfully, Anna Heinink Publisher, Expert Opinion

Informa Healthcare is a trading name of Informa UK Limited. Registered in England under no. 1072954 Registered Office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH

If you wish to unsubscribe, please click on the link below.
Please note this is an automated operation.
http://informahealthcare.msgfocus.com/u/18HKWto1lavLlBA

Disadvantaged face the hardest fight against cancer

Note: to cancer patients and their families this is not a surprise, I would suspect via media reports, past and present, that the public is wiser as well (aka: "the Wisdom of Crowds")

"To many Canadians this finding might come as a surprise."

Read more: http://www.vancouversun.com/health/Disadvantaged+face+hardest+fight+against+cancer/3384687/story.html#ixzz0wMeKYWYt